Ready with a 'stalking horse' bid from its lenders, embattled Akorn files for bankruptcy

Akorn aims to "execute an in-court sale" to lenders through a bankruptcy filing. (Pixabay)

Just since 2017, Akorn has been through a terminated sale, data tampering allegations, FDA warning letters and more. Now, it’s declaring bankruptcy to sell itself to its creditors. 

Through a Delaware bankruptcy filing Wednesday, Akorn plans to “execute an in‑court sale” with its lenders lodging a "stalking horse” offer. While Akorn plans to sell to those lenders, other potential buyers will have the opportunity to bid.

Meanwhile, the company plans to continue normal operations throughout the bankruptcy process, and it’s secured $30 million in financing to keep its operations running. The company hopes to complete the process by the third quarter of this year. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

It’s the latest twist in a tough three-year stretch for the company after it agreed to sell to Fresenius in April 2017. In May 2018, Fresenius said it had uncovered “blatant fraud at the very top level” of Akorn and sought to abandon the $4.3 billion buyout. A legal fight followed, but a judge eventually freed Fresenius from the buyout deal in October 2018. 

RELATED: Judge frees Fresenius from buyout, citing 'extensive and recurring' data problems at Akorn 

Since then, Akorn has been renegotiating its debt, and the FDA has reprimanded the company for problems at its factories in Lake Forest, Illinois, and Amityville, New York

Akorn’s bankruptcy filing lists up to $10 billion in debt and up to $10 billion in assets. 


Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.